Antinuclear Antibody Testing Market by Product (Reagents & Assay Kits, Services, Software), Technique (Enzyme-linked immunosorbent assay (ELISA), Indirect immunofluorescent (IIF), Multiplex immunoassay), Technology, Indication, End-User - Global Forecast

Antinuclear Antibody Testing Market by Product (Reagents & Assay Kits, Services, Software), Technique (Enzyme-linked immunosorbent assay (ELISA), Indirect immunofluorescent (IIF), Multiplex immunoassay), Technology, Indication, End-User - Global Forecast 2024-2030


The Antinuclear Antibody Testing Market size was estimated at USD 1.77 billion in 2023 and expected to reach USD 1.95 billion in 2024, at a CAGR 10.49% to reach USD 3.56 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antinuclear Antibody Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antinuclear Antibody Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antinuclear Antibody Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, Antibodies Incorporated, Arthrex, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., BIOGENIX INC. PVT. LTD., Boston Scientific Corporation, Erba Mannheim, EUROIMMUN Medizinische Labordiagnostika AG, F. Hoffmann-La Roche Ltd., Grifols, S.A., Immuno Concepts NA Ltd., Immunodiagnostic Systems, Inova Diagnostics, Inc., Laboratory Corporation of America Holdings, Organogenesis Inc., PerkinElmer, Inc., Quidel Corporation, Siemens Healthineers AG, Smith + Nephew PLC, Thermo Fisher Scientific Inc., Trinity Biotech PLC, ZEUS Scientific, Inc, and Zimmer Biomet Holdings, Inc.

Market Segmentation & Coverage

This research report categorizes the Antinuclear Antibody Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product

Reagents & Assay Kits
  • Services
  • Software
  • Technique

    Enzyme-linked immunosorbent assay (ELISA)
  • Indirect immunofluorescent (IIF)
  • Multiplex immunoassay
  • Technology

    Automated Testing
  • Manual Testing
  • Indication

    Juvenile Idiopathic Arthritis (JIA)
  • Rheumatoid Arthritis
  • Scleroderma
  • Sjögren's Syndrome
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Vasculitis
  • End-User

    Clinical Laboratories
  • Diagnostic Centers
  • Hospitals
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Antinuclear Antibody Testing Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antinuclear Antibody Testing Market?
    3. What are the technology trends and regulatory frameworks in the Antinuclear Antibody Testing Market?
    4. What is the market share of the leading vendors in the Antinuclear Antibody Testing Market?
    5. Which modes and strategic moves are suitable for entering the Antinuclear Antibody Testing Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Antinuclear Antibody Testing Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising prevalence of autoimmune diseases among population
    5.1.1.2. Government programs to create awareness for autoimmune diseases
    5.1.1.3. Growing healthcare expenditure and modernization of healthcare infrastructure
    5.1.2. Restraints
    5.1.2.1. Issues associated with accuracy of antinuclear antibody tests
    5.1.3. Opportunities
    5.1.3.1. Higher potential of fully automated antinuclear antibody IIA
    5.1.3.2. Emerging applications of AI and ML in antinuclear antibody pattern recognition
    5.1.4. Challenges
    5.1.4.1. Stringent and time consuming ANA product approval procedures
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Antinuclear Antibody Testing Market, by Product
    6.1. Introduction
    6.2. Reagents & Assay Kits
    6.3. Services
    6.4. Software
    7. Antinuclear Antibody Testing Market, by Technique
    7.1. Introduction
    7.2. Enzyme-linked immunosorbent assay (ELISA)
    7.3. Indirect immunofluorescent (IIF)
    7.4. Multiplex immunoassay
    8. Antinuclear Antibody Testing Market, by Technology
    8.1. Introduction
    8.2. Automated Testing
    8.3. Manual Testing
    9. Antinuclear Antibody Testing Market, by Indication
    9.1. Introduction
    9.2. Juvenile Idiopathic Arthritis (JIA)
    9.3. Rheumatoid Arthritis
    9.4. Scleroderma
    9.5. Sjögren's Syndrome
    9.6. Systemic Lupus Erythematosus (SLE)
    9.7. Systemic Vasculitis
    10. Antinuclear Antibody Testing Market, by End-User
    10.1. Introduction
    10.2. Clinical Laboratories
    10.3. Diagnostic Centers
    10.4. Hospitals
    11. Americas Antinuclear Antibody Testing Market
    11.1. Introduction
    11.2. Argentina
    11.3. Brazil
    11.4. Canada
    11.5. Mexico
    11.6. United States
    12. Asia-Pacific Antinuclear Antibody Testing Market
    12.1. Introduction
    12.2. Australia
    12.3. China
    12.4. India
    12.5. Indonesia
    12.6. Japan
    12.7. Malaysia
    12.8. Philippines
    12.9. Singapore
    12.10. South Korea
    12.11. Taiwan
    12.12. Thailand
    12.13. Vietnam
    13. Europe, Middle East & Africa Antinuclear Antibody Testing Market
    13.1. Introduction
    13.2. Denmark
    13.3. Egypt
    13.4. Finland
    13.5. France
    13.6. Germany
    13.7. Israel
    13.8. Italy
    13.9. Netherlands
    13.10. Nigeria
    13.11. Norway
    13.12. Poland
    13.13. Qatar
    13.14. Russia
    13.15. Saudi Arabia
    13.16. South Africa
    13.17. Spain
    13.18. Sweden
    13.19. Switzerland
    13.20. Turkey
    13.21. United Arab Emirates
    13.22. United Kingdom
    14. Competitive Landscape
    14.1. FPNV Positioning Matrix
    14.2. Market Share Analysis, By Key Player
    14.3. Competitive Scenario Analysis, By Key Player
    15. Competitive Portfolio
    15.1. Key Company Profiles
    15.1.1. Abbott Laboratories
    15.1.2. Abcam PLC
    15.1.3. Antibodies Incorporated
    15.1.4. Arthrex, Inc.
    15.1.5. Becton Dickinson and Company
    15.1.6. Bio-Rad Laboratories, Inc.
    15.1.7. BIOGENIX INC. PVT. LTD.
    15.1.8. Boston Scientific Corporation
    15.1.9. Erba Mannheim
    15.1.10. EUROIMMUN Medizinische Labordiagnostika AG
    15.1.11. F. Hoffmann-La Roche Ltd.
    15.1.12. Grifols, S.A.
    15.1.13. Immuno Concepts NA Ltd.
    15.1.14. Immunodiagnostic Systems
    15.1.15. Inova Diagnostics, Inc.
    15.1.16. Laboratory Corporation of America Holdings
    15.1.17. Organogenesis Inc.
    15.1.18. PerkinElmer, Inc.
    15.1.19. Quidel Corporation
    15.1.20. Siemens Healthineers AG
    15.1.21. Smith + Nephew PLC
    15.1.22. Thermo Fisher Scientific Inc.
    15.1.23. Trinity Biotech PLC
    15.1.24. ZEUS Scientific, Inc
    15.1.25. Zimmer Biomet Holdings, Inc
    15.2. Key Product Portfolio
    16. Appendix
    16.1. Discussion Guide
    16.2. License & Pricing
    FIGURE 1. ANTINUCLEAR ANTIBODY TESTING MARKET RESEARCH PROCESS
    FIGURE 2. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTINUCLEAR ANTIBODY TESTING MARKET DYNAMICS
    FIGURE 7. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
    FIGURE 8. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
    FIGURE 10. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
    FIGURE 12. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 14. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
    FIGURE 16. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 20. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. ANTINUCLEAR ANTIBODY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 26. ANTINUCLEAR ANTIBODY TESTING MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings